Related Experiment Video

Updated: Dec 30, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K

Targeting long non-coding RNA HERC2P3 inhibits cell growth and migration in human gastric cancer cells

Jingde Chen1, Hui Cai1,2, Yongsong Xie3

  • 1Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University Shanghai, China.

International Journal of Clinical and Experimental Pathology
|January 23, 2020
PubMed

Insights

Long non-coding RNA HERC2P3 (HERC2P3) promotes gastric cancer growth and migration. Silencing HERC2P3 inhibits these processes, suggesting HERC2P3 is a potential therapeutic target for gastric cancer.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Long non-coding RNAs (lncRNAs) play roles in cancer development.
  • The specific function of lncRNA HERC2P3 in gastric cancer remains largely unknown.
  • HERC2P3 is a pseudogene of HERC2, located on chromosome 15q11.1-q11.2.

Purpose of the Study:

  • To investigate the role of HERC2P3 in gastric cancer cell growth and migration.
  • To explore the underlying molecular mechanisms, including the involvement of Akt signaling.
  • To analyze HERC2P3 expression in human gastric cancer tissues.

Main Methods:

  • In vitro studies using CCK-8 and Transwell assays to assess cell growth and migration.
  • In vivo studies using a tumor-bearing mouse model.
  • Western blot analysis to examine Akt phosphorylation.
  • Quantitative RT-PCR to determine HERC2P3 expression in patient samples.

Main Results:

  • Silencing HERC2P3 significantly inhibited gastric cancer cell migration and, to a lesser extent, cell growth.
  • HERC2P3 knockdown led to reduced Akt phosphorylation, suggesting Akt signaling pathway involvement.
  • HERC2P3 was found to be upregulated in gastric adenocarcinoma tissues compared to non-tumor tissues.

Conclusions:

  • HERC2P3 promotes gastric cancer cell growth and migration.
  • Inhibition of HERC2P3 can suppress tumor progression.
  • HERC2P3 represents a potential therapeutic target for gastric cancer treatment.
Keywords:
HERC2P3cell migrationcell proliferationgastric cancerlncRNA

More Related Videos

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.1K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.0K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K